• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

Anti-Viral Inhibitor Binding to Influenza Neuraminidase by MALDI Mass Spectrometry

tetano

Editor, Senior Moderator
Anal Chem. 2012 Mar 12. [Epub ahead of print]
Anti-Viral Inhibitor Binding to Influenza Neuraminidase by MALDI Mass Spectrometry.
Swaminathan K, Downard KM.
Abstract

A MALDI mass spectrometry based approach is applied to identify active site domains within influenza neuraminidase that bind the anti-viral inhibitors zanamivir (ZANA) and 2-deoxy-2,3-didehydro-N-acetylneuraminic acid (DANA). Combined data from the tryptic and Glu-C endoproteinase digests of neuraminidase-inhibitor complexes have identified binding peptides that contain the active site residues Arg118, Glu119, Arg156, Glu276 and Tyr406. The binding of these residues was confirmed from the analysis of available X-ray crystal structures. The ability to identify peptides within the active sites of proteins and likely binding residues provides both a rapid and relatively high throughput approach with which to screen protein-drug interactions by MALDI mass spectrometry.

PMID:
22409142
[PubMed - as supplied by publisher]

http://www.ncbi.nlm.nih.gov/pubmed/22409142
 
Back
Top Bottom